Resources

Expert Q&A

Launching in EU – Q&A 4

What additional national regulatory requirements must we navigate after EMA approval?

Read more

Expert Q&A

First interactions with EMA – Q&A 7

What regulatory pathway missteps should we avoid, and how can we streamline our EU dossier preparation?

Read more

Expert Q&A

How does the EU drug development landscape differ from the US ?

How does the EU drug development landscape differ from the US ?

Read more

Expert Q&As

Launching in EU – Q&A 3

How to choose the right location for our European headquarters or hub?

Read more

Expert Q&A

Launching in EU – Q&A 2

Get expert insights for the Launch of your medicine in the EU. Learn how to choose the right regulatory pathway, compare timelines, and navigate EU procedures with confidence.

Read more

Expert Q&As

Why is launching a drug in Europe different from launching in the US?

Get expert insights for the Launch of your medicine in the EU. Learn how to choose the right regulatory pathway, compare timelines, and navigate EU procedures with confidence.

Read more

News

Exploitant Services in France for Pharmaceutical Companies

Ensure full compliance with French regulations through our exploitant services.

Read more

Expert Q&As

What are the different regulatory pathways available when expanding to Europe and which one is the best fit for me?

What are the different regulatory pathways available when expanding to Europe and which one is the best fit for me?

Read more

White Papers

Avoid those 6 common mistakes and file a successful Marketing Authorization with the EMA.

Discover 6 common mistakes that derail EMA marketing authorization filings. Learn how first-time applicants can avoid delays with practical tips and regulatory insights.

Read more

White Papers

How to confidently navigate your first EMA interactions

A practical guide for biopharma companies preparing for their first EMA interaction. Learn 5 critical steps to reduce delays and align with EU regulatory expectations.

Read more